Novartis AG (VTX:NOVN) has been given a CHF 80 price target by equities researchers at Goldman Sachs Group, Inc. (The) in a report released on Tuesday, October 17th. The brokerage presently has a “neutral” rating on the stock. Goldman Sachs Group, Inc. (The)’s target price indicates a potential downside of 4.93% from the stock’s previous close.
Several other research firms also recently issued reports on NOVN. Deutsche Bank AG set a CHF 78 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Wednesday, June 21st. S&P Global set a CHF 82 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Tuesday, July 18th. Barclays PLC set a CHF 80 price target on shares of Novartis AG and gave the stock a “neutral” rating in a research note on Friday, June 23rd. Jefferies Group LLC set a CHF 103 target price on shares of Novartis AG and gave the stock a “buy” rating in a research report on Friday, June 23rd. Finally, Morgan Stanley set a CHF 88 target price on shares of Novartis AG and gave the stock a “buy” rating in a research report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. Novartis AG presently has an average rating of “Hold” and an average target price of CHF 86.10.
Novartis AG (VTX:NOVN) remained flat at $CHF 83.60 during trading hours on Tuesday. 2,720,000 shares of the company’s stock were exchanged, compared to its average volume of 4,040,000. Novartis AG has a 52 week low of CHF 67.40 and a 52 week high of CHF 85.40.
TRADEMARK VIOLATION NOTICE: This report was originally reported by BBNS and is owned by of BBNS. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://baseballnewssource.com/markets/goldman-sachs-group-inc-the-analysts-give-novartis-ag-novn-a-chf-80-price-target/1720654.html.
Novartis AG Company Profile
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.